Carna Biosciences Inc
TSE:4572
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| JP |
|
Carna Biosciences Inc
TSE:4572
|
6.7B JPY |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
979.9B USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.8B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
135.4B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
33B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
264.5B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.5B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
28.9B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28.3B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24.3B USD |
Loading...
|
Market Distribution
| Min | -179.8% |
| 30th Percentile | 21.8% |
| Median | 30.6% |
| 70th Percentile | 42.3% |
| Max | 18 197.9% |
Other Profitability Ratios
Carna Biosciences Inc
Glance View
Carna Biosciences, Inc. engages in the drug discovery business. The company is headquartered in Kobe, Hyogo-Ken and currently employs 64 full-time employees. The company went IPO on 2008-03-25. The firm operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Carna Biosciences Inc is 67%, which is below its 3-year median of 79.6%.
Over the last 3 years, Carna Biosciences Inc’s Gross Margin has decreased from 87.6% to 67%. During this period, it reached a low of 67% on Jan 31, 2026 and a high of 89.2% on Dec 31, 2023.
